Cancer Biomarkers Market - Trends and Forecast Till 2035

CANCER BIOMARKERS MARKET OVERVIEW

The global cancer biomarkers market is estimated to reach from USD 25.9 billion in the current year to USD 37.8 billion by 2035, expanding at a CAGR of 4.3%during the forecast period.

Cancer Biomarkers Market: Growth and Trends

Cancer biomarkers have become an important component of modern oncology as clinicians and drug developers increasingly seek molecular information to understand tumor biology and identify patients who are most likely to respond to specific therapies. Conventional approaches based primarily on cancer type and disease stage are increasingly being supplemented by molecular profiling, including biomarker testing for HER2, EGFR, PD-L1, ALK, NTRK and MET, alongside broader genomic indicators such as tumor mutational burden, microsatellite instability, single nucleotide variants, copy number variants and insertions and deletions.

The cancer biomarkers market is transitioning from conventional single-analyte testing toward integrated molecular profiling and multi-biomarker approaches. Increasing investments in precision medicine have encouraged pharmaceutical and biotechnology companies to incorporate biomarker strategies across drug discovery, clinical development, patient stratification and post-treatment monitoring. The growing pipeline of targeted oncology therapies is also expanding the need for companion and complementary diagnostic solutions. Biomarker testing can support identification of eligible patients, treatment selection and assessment of therapeutic response, thereby creating a closer link between oncology drug development and diagnostic testing.

Technological advancements are further changing the competitive landscape. Next-generation sequencing and liquid biopsy platforms are enabling the analysis of multiple genomic alterations from increasingly limited biological samples, while artificial intelligence and digital pathology are being explored to improve biomarker identification, interpretation and clinical decision-making. The combination of molecular diagnostics with real-world data and advanced analytics is expected to create additional opportunities across the oncology value chain.

Growth Drivers: Factors Fueling Cancer Biomarkers Market Expansion

Increasing incidence of breast, lung, colorectal, prostate and other cancers is expanding the addressable population for diagnostic, prognostic and predictive biomarker testing. The growing need for earlier and more precise disease characterization is supporting demand for molecular testing solutions. Healthcare providers and pharmaceutical companies are increasingly using molecular information to guide treatment selection. This is creating sustained demand for biomarkers that can identify actionable mutations, predict treatment response and support patient stratification.

Market Challenges: Critical Barriers Hindering Progress

Despite strong demand, several factors continue to influence the pace of market development. Discovery, analytical validation, clinical validation and regulatory approval can require substantial financial and technical resources. Long development timelines can also make it difficult for smaller companies to commercialize novel biomarker technologies.

Several emerging biomarkers require additional evidence demonstrating clinical utility across diverse patient populations. Lack of sufficiently large and representative datasets can delay adoption in routine oncology practice. Differences in assay methodologies, reporting formats, laboratory protocols and clinical datasets can complicate the integration and comparison of biomarker results.

Cancer Biomarkers Market: Emerging Opportunity Areas

Liquid Biopsy And Circulating Biomarkers: Liquid biopsy represents an important opportunity for non-invasive cancer detection and molecular monitoring. Continued improvements in sensitivity may expand applications across early detection, treatment selection, minimal residual disease monitoring and recurrence assessment.

Multi-Biomarker And Comprehensive Genomic Profiling: The growing complexity of cancer biology is creating demand for testing approaches capable of evaluating multiple genomic alterations simultaneously. Comprehensive profiling can support identification of actionable molecular changes across heterogeneous tumors.

AI-Powered Biomarker Discovery: Artificial intelligence can help analyze large genomic, pathological and clinical datasets to identify previously unrecognized molecular patterns. Integration of AI with digital pathology and multi-omics could create new biomarker discovery and interpretation opportunities.

Recent Developments in Cancer Biomarkers Market

The market is witnessing increased collaboration between diagnostic technology companies, pharmaceutical companies and data-driven oncology platforms.

Illumina and Labcorp entered into a collaboration to advance precision oncology testing capabilities, with initiatives focused on expanding access to cancer biomarker testing.
Lunit and Daiichi Sankyo partnered to advance biomarker discovery and translational research by integrating AI-powered digital pathology solutions into oncology pipeline programs.
Tempus AI and Whitehawk Therapeutics collaborated to use real-world data to support biomarker-driven research and oncology pipeline development.

These developments demonstrate the increasing convergence of molecular diagnostics, artificial intelligence, real-world data and pharmaceutical R&D within the cancer biomarker ecosystem.

Cancer Biomarkers Market Segments

By Type of Biomarker

HER2
MET
EGFR
PD-L1
NTRK
ALK
Other Biomarkers

By Type of Cancer

Breast Cancer
Colorectum Cancer
Lung Cancer
Prostate Cancer
Thyroid Cancer
Bladder Cancer
Melanoma
Non-Hodgkin Lymphoma
Endometrial Cancer
Kidney Cancer
Leukemia

By Geographical Regions

North America
Europe
Asia-Pacific
Latin America
Middle East and North Africa

Cancer Biomarkers Market: Key Segmentation Insights

HER2 Biomarkers Maintain A Strong Market Position

HER2 biomarkers represent a major established segment due to extensive clinical validation and their role in breast and gastric cancer management. HER2 testing is also closely associated with targeted therapies, supporting continued demand across diagnostic laboratories and oncology care settings. EGFR represents an important growth opportunity as precision treatment strategies expand in lung cancer and other relevant indications.

The broader biomarker landscape is also expanding beyond individual molecular targets. TMB, MSI, SNVs, CNVs and indels are increasingly relevant for understanding tumor biology and supporting personalized treatment strategies.

Breast Cancer Represents A Major Application Area

Breast cancer represents a major application area due to the established use of molecular biomarkers for diagnosis, prognosis, risk assessment and treatment selection. Lung cancer is another important application area because of the increasing relevance of molecular testing for targeted treatment selection.

Melanoma also presents opportunities for biomarker testing as targeted therapies and molecular diagnostics continue to develop. Biomarkers associated with BRAF and other molecular alterations can support treatment-selection strategies, while liquid biopsy approaches may expand the scope of molecular monitoring.

North America Leads The Cancer Biomarkers Market

North America represents the largest regional market, supported by advanced healthcare infrastructure, high adoption of precision medicine, established diagnostic networks, strong pharmaceutical R&D activity and increasing use of molecular oncology testing.

Europe represents another important market due to its established oncology research ecosystem and increasing integration of molecular diagnostics into cancer care. Asia-Pacific offers significant expansion opportunities as cancer diagnosis rates increase and healthcare systems invest in genomic testing, precision medicine and advanced laboratory infrastructure.

Latin America and the Middle East and Africa are also expected to present opportunities as access to cancer diagnostics improves and healthcare providers increasingly adopt advanced molecular testing technologies.

Example Players in Cancer Biomarkers Market

ARUP Laboratories
Asper Biogene
BioReference
Caris Life Sciences
CeGaT
Foundation Medicine
Genekor Medical
Guardant Health
IQVIA Laborateries
Labcorp
MedGenome
NeoGenomics Laboratories
Nonacus
OncoDNA
Quest Diagnostics
Oxford Gene Technology
Personal Genome Diagnostics
PhenoPath
Positive Biosciences
Tempus
Thermo Fisher Scientific
YuceBio

Expert Interview and Industry Insights

The market report includes transcripts of the following discussions:

Chief Technical Officer and Former Director of Preclinical Development & Strategic Partnerships, Small Company, US
Business Manager, Mid-sized Company, Germany
Former Chief Scientific Officer, Large Company, US

Industry Experts on Cancer Biomarkers Market

The market report includes transcripts of the following other third-party discussions:

Doctor of Medicine, Research Organization, US, North America
Professor, Research University, UK, Europe
Doctor of Medicine, Research Organization, US, North America
Professor, Research University, US, North America
Doctor of Medicine, Research Organization, US, North America
Professor, Research University, US, North America
Oncologist, Hospital, US, North America
Professor, Research University, US, North America
Lead of Cancer Genomics, Research University, Australia, Asia-Pacific
Professor, Research University, US, North America

CANCER BIOMARKERS MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report provides an in-depth assessment of the cancer biomarkers market, focusing on key segments including type of biomarker, type of cancer and geographical regions. The analysis provides market size forecasts, historical trends and opportunity assessment across major market segments.
Competitive Landscape: Evaluation of leading companies operating across the cancer biomarkers ecosystem, including diagnostic laboratories, genomic testing companies, biotechnology firms and precision oncology providers.
Company Profiles: In-depth profiles of prominent cancer biomarker companies covering company overview, product and service portfolio, biomarker capabilities, business activities and key strategic initiatives.
Product Competitiveness Analysis: Comparative evaluation of cancer biomarker testing solutions offered by providers across North America, Europe, and Asia-Pacific, including assessment of peer groups and regional product portfolios.
Company Profiles: Detailed profiles of leading cancer biomarker testing solution providers, including Agilent, ARUP Laboratories, Asper Biogene, BioReference, Caris Life Sciences, Foundation Medicine, Guardant Health, Labcorp, Quest Diagnostics, Tempus AI, Thermo Fisher Scientific, and other key players, with a focus on company overview and testing solution portfolios.
Innovative Study Designs: Analysis of biomarker-based clinical trial designs, including enrichment, all-comers, mixture/hybrid, and adaptive designs, along with relevant regulatory guidelines.
Clinical Trial Analysis: Comprehensive assessment of cancer biomarker clinical trials by registration year, trial status, phase, patient population, gender, study design, sponsor or collaborator, and geography, including analysis of leading industry and non-industry participants.
Publication Analysis: Evaluation of cancer biomarker publications by publication year, publication type, cancer type, copyright holder, emerging focus areas, leading publishers, and key journals based on impact factor and publication volume.
Big Pharma Benchmarking: Comparative benchmarking of major pharmaceutical companies based on their cancer biomarker activities and strategic positioning, supported by company-level spider web analysis.
Value Chain Analysis: Case study assessing the companion diagnostics value chain, including cost distribution across research and product development, manufacturing and assembly, clinical trials and regulatory activities, payer negotiations, KOL engagement, marketing, and sales.

CANCER BIOMARKERS MARKET: KEY QUESTIONS ANSWERED

What is the current market size of the global cancer biomarkers market?
What will be the market size of cancer biomarkers by 2035?
Which type of cancer biomarker currently represents the largest market opportunity?
Which cancer types generate the greatest demand for biomarker testing?
What are the major factors driving adoption of cancer biomarkers?
What are the key challenges limiting biomarker development and commercialization?
How are liquid biopsy and next-generation sequencing changing the biomarker landscape?
What role will artificial intelligence play in cancer biomarker discovery and interpretation?
How is the growing adoption of precision oncology influencing biomarker demand?
What opportunities exist for companion diagnostic developers?
Which regions represent significant growth opportunities for cancer biomarker companies?
Who are the leading companies operating in the cancer biomarkers market?
What strategic partnerships and collaborations are shaping the competitive landscape?
What are the emerging opportunities across multi-omics, liquid biopsy, AI-powered diagnostics and real-world data?
How is the competitive landscape expected to evolve through 2035?

WHY BUY THIS CANCER BIOMARKERS MARKET REPORT?

This report provides stakeholders with a structured view of the evolving cancer biomarkers ecosystem and the commercial opportunities emerging across diagnostics, pharmaceutical R&D and precision oncology.
The analysis can support market entry strategies, investment assessment, product portfolio planning, competitive benchmarking, partnership identification and regional expansion decisions.
The report is particularly relevant for biomarker developers, diagnostic companies, pharmaceutical and biotechnology companies, clinical laboratories, companion diagnostic developers, sequencing technology providers, investors, contract research organizations and healthcare organizations seeking to assess current market opportunities and emerging technology trends.
The report includes 336 pages of analysis, historical market trends, forecasts through 2035, more than 140 figures and 135+ market data tables, along with company profiles and industry insights.

ADDITIONAL BENEFITS

Complementary PPT Insights Pack
Complementary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated Report if the Report is 6-12 Months Old or Older

1. PREFACE

1.1. Introduction
1.2. Report Coverage
1.3. Market Segmentation
1.4. Key Market Insights
1.5. Market Share Insights
1.6. Key Questions Answered

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. ECONOMIC AND OTHER PROJECT-SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Cancer Biomarker Testing Solutions: Market Landscape
5.2. Cancer Biomarker Testing Solutions: Market Trends
5.3. Cancer Biomarker Testing Solutions: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Chapter Overview
6.2. An Overview of Cancer Biomarkers
6.2.1. Need for Cancer Biomarkers
6.2.2. Identification of a Candidate Biomarker
6.3. Type of Cancer Biomarkers
6.4. Novel Cancer Biomarkers
6.4.1. Tumor Mutation Burden (TMB)
6.4.1.1. Variation of TMB across Multiple Indications
6.4.1.2. Methods for Measurement of TMB
6.4.1.3. Factors Affecting Measurement of TMB
6.4.1.4. Initiatives for Assessment of TMB as a Potential Biomarker
6.4.2. Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)
6.4.2.1. Variation of MSI across Multiple Indications
6.4.2.2. Methods for Measurement of MSI
6.4.3. Single Nucleotide Variants (SNVs)
6.4.3.1. Variation of SNV across Multiple Indications
6.4.3.2. Methods for Measurement of SNV
6.4.4. Copy Number Variants (CNVs)
6.4.4.1. Variation of CNV across Multiple Cancer Indications
6.4.4.2. Methods for Measurement of CNV
6.4.5. Indels and Other Novel Biomarkers
6.5. Future Perspective

7. MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Cancer Biomarker Testing Solutions: Overall Market Landscape
7.2.1. Analysis by Type of Biomarker Evaluated
7.2.2. Analysis by Type of Analytical Technique Used
7.2.3. Analysis by Turnaround Time
7.2.4. Analysis by Type of Sample Supported
7.2.5. Analysis by Type of Nucleic Acid Tested
7.2.6. Analysis by Type of Cancer
7.2.7. Analysis by Application Area
7.2.8. Analysis by End-user
7.3. Cancer Biomarkers Testing Solutions: Provider Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Most Active Player: Analysis by Number of Testing Solutions Offered

8. PRODUCT COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Assumptions / Key Parameters
8.3. Methodology
8.4. Overview of Peer Groups
8.5. Cancer Biomarkers Testing Solutions: Product Competitiveness Analysis
8.5.1. Cancer Biomarker Testing Solutions Offered by Providers Headquartered in North America
8.5.2. Cancer Biomarker Testing Solutions Offered by Providers Headquartered in Europe
8.5.3. Cancer Biomarker Testing Solutions Offered by Providers Headquartered in Asia-Pacific

9. COMPANY PROFILES: CANCER BIOMARKERS TESTING SOLUTION PROVIDERS

9.1. Chapter Overview
9.2. Agilent
9.2.1. Company Overview
9.2.2. Cancer Biomarker Testing Solutions Portfolio
9.3. ARUP Laboratories
9.3.1. Company Overview
9.3.2. Cancer Biomarker Testing Solutions Portfolio
9.4. Asper Biogene
9.4.1. Company Overview
9.4.2. Cancer Biomarker Testing Solutions Portfolio
9.5. BioReference
9.5.1. Company Overview
9.5.2. Cancer Biomarker Testing Solutions Portfolio
9.6. Caris Life Sciences
9.6.1. Company Overview
9.6.2. Cancer Biomarker Testing Solutions Portfolio
9.7. CeGaT
9.7.1. Company Overview
9.7.2. Cancer Biomarker Testing Solutions Portfolio
9.8. Foundation Medicine
9.8.1. Company Overview
9.8.2. Cancer Biomarker Testing Solutions Portfolio
9.9. Genekor Medical
9.9.1. Company Overview
9.9.2. Cancer Biomarker Testing Solutions Portfolio
9.10. Guardant Health
9.10.1. Company Overview
9.10.2. Cancer Biomarker Testing Solutions Portfolio
9.11. IQVIA Laboratories
9.11.1. Company Overview
9.11.2. Cancer Biomarker Testing Solutions Portfolio
9.12. Labcorp
9.12.1. Company Overview
9.12.2. Cancer Biomarker Testing Solutions Portfolio
9.13. MedGenome
9.13.1. Company Overview
9.13.2. Cancer Biomarker Testing Solutions Portfolio
9.14. NeoGenomics Laboratories
9.14.1. Company Overview
9.14.2. Cancer Biomarker Testing Solutions Portfolio
9.15. Nonacus
9.15.1. Company Overview
9.15.2. Cancer Biomarker Testing Solutions Portfolio
9.16. OncoDNA
9.16.1. Company Overview
9.16.2. Cancer Biomarker Testing Solutions Portfolio
9.17. Quest Diagnostics
9.17.1. Company Overview
9.17.2. Cancer Biomarker Testing Solutions Portfolio
9.18. Oxford Gene Technology
9.18.1. Company Overview
9.18.2. Cancer Biomarker Testing Solutions Portfolio
9.19. Personal Genome Diagnostics
9.19.1. Company Overview
9.19.2. Cancer Biomarker Testing Solutions Portfolio
9.20. PhenoPath
9.20.1. Company Overview
9.20.2. Cancer Biomarker Testing Solutions Portfolio
9.21. Positive Biosciences
9.21.1. Company Overview
9.21.2. Cancer Biomarker Testing Solutions Portfolio
9.22. Tempus AI
9.22.1. Company Overview
9.22.2. Cancer Biomarker Testing Solutions Portfolio
9.23. Thermo Fisher Scientific
9.23.1. Company Overview
9.23.2. Cancer Biomarker Testing Solutions Portfolio
9.24. YuceBio
9.24.1. Company Overview
9.24.2. Cancer Biomarker Testing Solutions Portfolio

10. INNOVATIVE STUDY DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS

10.1. Chapter Overview
10.2. Study Designs for Biomarker-based Clinical Trials
10.2.1. Enrichment Design
10.2.2. All-comers Design
10.2.3. Mixture / Hybrid Design
10.2.4. Adaptive Design
10.3. Regulatory Guidelines for Biomarker-based Clinical Trial Designs
10.4. Conclusion

11. CLINICAL TRIAL ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Cancer Biomarkers: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis of Patients Enrolled by Trial Registration Year
11.3.3. Analysis by Trial Status
11.3.4. Analysis by Trial Registration Year and Trial Status
11.3.5. Analysis by Trial Phase
11.3.6. Analysis of Enrolled Patient Population by Trial Phase
11.3.7. Analysis by Patient Gender
11.3.8. Analysis by Study Design
11.3.8.1. Analysis by Type of Allocation
11.3.8.2. Analysis by Type of Intervention Model
11.3.8.3. Analysis by Type of Masking
11.3.8.4. Analysis by Type of Primary Purpose
11.3.9. Analysis by Type of Sponsor / Collaborator
11.3.10. Most Active Industry Player: Analysis by Number of Registered Trials
11.3.11. Most Active Non-Industry Player: Analysis by Number of Registered Trials
11.3.12. Analysis of Clinical Trials by Geography
11.3.13. Analysis of Clinical Trials by Trial Status and Geography
11.3.14. Analysis of Patients Enrolled by Trial Status and Geography

12. PUBLICATION ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Cancer Biomarkers: Publication Analysis
12.3.1. Analysis by Year of Publication
12.3.2. Analysis by Type of Publication
12.3.3. Analysis by Type of Cancer
12.3.4. Analysis by Copyright Holders
12.3.5. Word Cloud: Emerging Focus Areas
12.3.6. Most Active Publishers: Analysis by Number of Publications
12.3.7. Key Journals: Analysis by Impact Factor
12.3.8. Key Journals: Analysis by Number of Publications

13. BIG PHARMA PLAYERS: BENCHMARK ANALYSIS

13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Big Pharma Players: Benchmarking Analysis
13.3.1. Spider Web Analysis: Abbott
13.3.2. Spider Web Analysis: AbbVie
13.3.3. Spider Web Analysis: Amgen
13.3.4. Spider Web Analysis: AstraZeneca
13.3.5. Spider Web Analysis: Bayer
13.3.6. Spider Web Analysis: Boehringer Ingelheim
13.3.7. Spider Web Analysis: Bristol-Myers Squib
13.3.8. Spider Web Analysis: Eli Lilly
13.3.9. Spider Web Analysis: Gilead
13.3.10. Spider Web Analysis: GlaxoSmithKline
13.3.11. Spider Web Analysis: Merck
13.3.12. Spider Web Analysis: Novartis
13.3.13. Spider Web Analysis: Pfizer
13.3.14. Spider Web Analysis: Roche
13.3.15. Spider Web Analysis: Sanofi
13.4. Concluding Remarks

14. CASE STUDY: ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY

14.1. Chapter Overview
14.2. Companion Diagnostics: Value Chain
14.3. Cost Distribution Across the Value Chain
14.3.1. Costs Associated with Research and Product Development
14.3.2. Costs Associated with Manufacturing and Assembly
14.3.3. Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
14.3.4. Costs Associated with Payer Negotiation and KOL Engagement
14.3.5. Costs Associated with Marketing and Sales

15. CASE STUDY: FUTURE GROWTH OPPORTUNITIES IN CANCER BIOMARKERS INDUSTRY

15.1. Chapter Overview
15.1.1. Growing Focus on Personalized Medicines
15.1.2. Rising need for Biomarker Testing for Various Oncological Disorders
15.1.3. Increase in Number of Biomarker-based Clinical Trials
15.1.4. Increased Adoption of Emerging Analytical Techniques for Biomarker Assessment
15.1.5. Development of Companion Diagnostic Products
15.2. Conclusion

16. GLOBAL CANCER BIOMARKERS MARKET

16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Cancer Biomarkers Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
16.3.1. Scenario Analysis
16.3.1.1. Conservative Scenario
16.3.1.2. Optimistic Scenario
16.4. Key Market Segmentations

17. CANCER BIOMARKERS MARKET, BY TYPE OF BIOMARKER

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cancer Biomarkers Market: Distribution by Type of Biomarker
17.3.1. Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.3.2. Cancer Biomarkers Market for MET Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.3.3. Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.3.4. Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.3.5. Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.3.6. Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.3.7. Cancer Biomarkers Market for Other Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.4. Cancer Biomarkers Market: Distribution of Novel Biomarkers
17.4.1. Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.4.2. Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.4.3. Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.4.4. Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.4.5. Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.4.6. Cancer Biomarkers Market for Indel Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
17.5. Data Triangulation and Validation

18. CANCER BIOMARKERS MARKET, BY TYPE OF CANCER

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Cancer Biomarkers Market: Distribution by Type of Cancer
18.3.1. Cancer Biomarkers Market for Breast Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.2. Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.3. Cancer Biomarkers Market for Lung Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.4. Cancer Biomarkers Market for Prostate Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.5. Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.6. Cancer Biomarkers Market for Bladder Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.7. Cancer Biomarkers Market for Melanoma: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.8. Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.9. Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.10. Cancer Biomarkers Market for Kidney Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.3.11. Cancer Biomarkers Market for Leukemia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation

19. CANCER BIOMARKERS MARKET, BY GEOGRAPHICAL REGIONS

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Cancer Biomarkers Market: Distribution by Geographical Regions
19.3.1. Cancer Biomarkers Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.1.1. North America Cancer Biomarkers Market in the US: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.1.2. North America Cancer Biomarkers Market in Canada: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.2. Cancer Biomarkers Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.2.1. Europe Cancer Biomarkers Market in Germany: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.2.2. Europe Cancer Biomarkers Market in France: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.2.3. Europe Cancer Biomarkers Market in the UK: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.2.4. Europe Cancer Biomarkers Market in Italy: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.2.5. Europe Cancer Biomarkers Market in Spain: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.3. Cancer Biomarkers Market in Aisa-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.3.1. Asia-Pacific Cancer Biomarkers Market in China: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.3.2. Asia-Pacific Cancer Biomarkers Market in Japan: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.3.3. Asia-Pacific Cancer Biomarkers Market in India: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.3.4. Asia-Pacific Cancer Biomarkers Market in South Korea: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.3.5. Asia-Pacific Cancer Biomarkers Market in Australia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.3.6. Asia-Pacific Cancer Biomarkers Market in New Zealand: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.4. Cancer Biomarkers Market in Latin America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.4.1. Latin America Cancer Biomarkers Market in Brazil: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.4.2. Latin America Cancer Biomarkers Market in Argentina: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.4.3. Latin America Cancer Biomarkers Market in Chile: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.5. Cancer Biomarkers Market in Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.3.5.1. Middle East and North Africa Cancer Biomarkers Market in Egypt: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
19.4. Market Dynamics Assessment
19.4.1. Penetration Growth (P-G) Matrix
19.4.2. Market Movement Analysis
19.5. Data Triangulation and Validation
**Detailed information on cross sectional analysis is available in the Excel Data Packs shared along with the report**

20. CONCLUDING REMARKS

21. EXECUTIVE INSIGHTS

21.1. Chapter Overview
21.2. Company A
21.2.1. Company Snapshot
21.2.2. Interview Transcript: Chief Technical Officer and Former Director of Preclinical Development & Strategic Partnerships
21.3. Company B
21.3.1. Company Snapshot
21.3.2. Interview Transcript: Former Chief Scientific Officer
21.4. Company C
21.4.1. Company Snapshot
21.4.2. Interview Transcript: Business Manager

22. APPENDIX 1: TABULATED DATA23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

Table 6.1 List of Cancer Biomarker Testing Solution Providers
Table 7.1 Cancer Biomarkers Testing Solutions: Information on Type of Biomarker Evaluated
Table 7.2 Cancer Biomarkers Testing Solutions: Information on Analytical Technique Used
Table 7.3 Cancer Biomarkers Testing Solutions: Information on Turnaround Time, Type of Sample Supported and Type of Nucleic Acid Tested
Table 7.4 Cancer Biomarkers Testing Solutions: Information on Type of Cancer
Table 7.5 Cancer Biomarkers Testing Solutions: Information on Application Area and End-user
Table 9.1 Cancer Biomarkers Testing Solution Providers: List of Companies Profiled
Table 9.2 Agilent: Company Overview
Table 9.3 Agilent: Cancer Biomarkers Testing Solutions Portfolio
Table 9.4 ARUP Laboratories: Company Overview
Table 9.5 ARUP Laboratories: Cancer Biomarker Testing Solutions Portfolio
Table 9.6 Asper Biogene: Company Overview
Table 9.7 Asper Biogene: Cancer Biomarkers Testing Solutions Portfolio
Table 9.8 BioReference: Company Overview
Table 9.9 BioReference: Cancer Biomarker Testing Solutions Portfolio
Table 9.10 Caris Life Sciences: Company Overview
Table 9.11 Caris Life Sciences: Cancer Biomarkers Testing Solutions Portfolio
Table 9.12 CeGaT: Company Overview
Table 9.13 CeGaT: Cancer Biomarkers Testing Solutions Portfolio
Table 9.14 Foundation Medicine: Company Overview
Table 9.15 Foundation Medicine: Cancer Biomarker Testing Solutions Portfolio
Table 9.16 Genekor Medical: Company Overview
Table 9.17 Genekor Medical: Cancer Biomarkers Testing Solutions Portfolio
Table 9.18 Guardant Health: Company Overview
Table 9.19 Guardant Health: Cancer Biomarkers Testing Solutions Portfolio
Table 9.20 IQVIA Laboratories: Company Overview
Table 9.21 IQVIA Laboratories: Cancer Biomarkers Testing Solutions Portfolio
Table 9.22 Labcorp: Company Overview
Table 9.23 Labcorp: Cancer Biomarkers Testing Solutions Portfolio
Table 9.24 MedGenome: Company Overview
Table 9.25 MedGenome: Cancer Biomarkers Testing Solutions Portfolio
Table 9.26 NeoGenomics Laboratories: Company Overview
Table 9.27 NeoGenomics Laboratories: Cancer Biomarkers Testing Solutions Portfolio
Table 9.28 Nonacus: Company Overview
Table 9.29 Nonacus: Cancer Biomarkers Testing Solutions Portfolio
Table 9.30 OncoDNA: Company Overview
Table 9.31 OncoDNA: Cancer Biomarker Testing Solutions Portfolio
Table 9.32 Quest Diagnostics: Company Overview
Table 9.33 Quest Diagnostics: Cancer Biomarker Testing Solutions Portfolio
Table 9.34 Oxford Gene Technology: Company Overview
Table 9.35 Oxford Gene Technology: Cancer Biomarkers Testing Solutions Portfolio
Table 9.36 Personal Genome Diagnostics: Company Overview
Table 9.37 Personal Genome Diagnostics: Cancer Biomarkers Testing Solutions Portfolio
Table 9.38 PhenoPath: Company Overview
Table 9.39 PhenoPath: Cancer Biomarkers Testing Solutions Portfolio
Table 9.40 Positive Biosciences: Company Overview
Table 9.41 Positive Biosciences: Cancer Biomarkers Testing Solutions Portfolio
Table 9.42 Tempus AI: Company Overview
Table 9.43 Tempus AI: Cancer Biomarkers Testing Solutions Portfolio
Table 9.44 Thermo Fisher Scientific: Company Overview
Table 9.45 Thermo Fisher Scientific: Cancer Biomarker Testing Solutions Portfolio
Table 9.46 YuceBio: Company Overview
Table 9.47 YuceBio: Cancer Biomarker Testing Solutions Portfolio
Table 21.1 Cell IDx: Company Snapshot
Table 21.2 NeoGenomics Laboratories: Company Snapshot
Table 21.3 CeGat: Company Snapshot
Table 22.1 Cancer Biomarker Testing Solutions: Distribution by Type of Biomarker Evaluated
Table 22.2 Cancer Biomarker Testing Solutions: Distribution by Analytical Technique Used
Table 22.3 Cancer Biomarker Testing Solutions: Distribution by Turnaround Time
Table 22.4 Cancer Biomarker Testing Solutions: Distribution by Type of Sample Supported
Table 22.5 Cancer Biomarker Testing Solutions: Distribution by Type of Nucleic Acid Tested
Table 22.6 Cancer Biomarker Testing Solutions: Distribution by Type of Cancer
Table 22.7 Cancer Biomarker Testing Solutions: Distribution by Application Area
Table 22.8 Cancer Biomarker Testing Solutions: Distribution by End-user
Table 22.9 Cancer Biomarker Testing Solution Providers: Distribution by Year of Establishment
Table 22.10 Cancer Biomarker Testing Solution Providers: Distribution by Company Size
Table 22.11 Cancer Biomarker Testing Solution Providers: Distribution by Location of Headquarters (Region)
Table 22.12 Cancer Biomarker Testing Solution Providers: Distribution by Most Active Players
Table 22.13 Clinical Trial Analysis: Distribution by Trial Registration Year, 2022-2025
Table 22.14 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, 2022-2025
Table 22.15 Clinical Trial Analysis: Distribution by Trial Status
Table 22.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 22.17 Clinical Trial Analysis: Distribution by Trial Phase
Table 22.18 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 22.19 Clinical Trial Analysis: Distribution by Patient Gender
Table 22.20 Clinical Trial Analysis: Distribution by Study Design
Table 22.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 22.22 Most Active Industry Players: Distribution by Number of Registered Trials
Table 22.23 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 22.24 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 22.25 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 22.26 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 22.27 Publication Analysis: Cumulative Year-wise Trend of Publications, 2019-2023
Table 22.28 Publication Analysis: Distribution by Type of Publication
Table 22.29 Publication Analysis: Distribution by Type of Cancer
Table 22.30 Copyright Holders: Distribution by Number of Publications
Table 22.31 Most Active Publishers: Distribution by Number of Publications
Table 22.32 Key Journals: Distribution by Impact Factor
Table 22.33 Key Journals: Distribution by Number of Publications
Table 22.34 Benchmarking Analysis: Big Pharma players
Table 22.35 Global Cancer Biomarkers Market: Since 2021, Till 2035 (USD Billion) Conservative, Base and Optimistic
Table 22.36 Cancer Biomarkers Market: Distribution by Type of Biomarker
Table 22.37 Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.38 Cancer Biomarkers Market for MET Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.39 Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.40 Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.41 Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.42 Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.43 Cancer Biomarkers Market for Other Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.44 Cancer Biomarkers Market: Distribution of Novel Biomarker
Table 22.45 Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.46 Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.47 Cancer Biomarkers Market for Indel Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.48 Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.49 Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.50 Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.51 Cancer Biomarkers Market: Distribution by Type of Cancer
Table 22.52 Cancer Biomarkers Market for Breast Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.53 Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.54 Cancer Biomarkers Market for Lung Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.55 Cancer Biomarkers Market for Prostate Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.56 Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.57 Cancer Biomarkers Market for Bladder Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.58 Cancer Biomarkers Market for Melanoma: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.59 Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.60 Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.61 Cancer Biomarkers Market for Kidney Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.62 Cancer Biomarkers Market for Leukemia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.63 Cancer Biomarkers Market: Distribution by Key Geographical Regions
Table 22.64 Cancer Biomarkers Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.65 North America Cancer Biomarkers Market in the US: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.66 North America Cancer Biomarkers Market in Canada: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.67 Cancer Biomarkers Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.68 Europe Cancer Biomarkers Market in Germany: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.69 Europe Cancer Biomarkers Market in France: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.70 Europe Cancer Biomarkers Market in the UK: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.71 Europe Cancer Biomarkers Market in Italy: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.72 Europe Cancer Biomarkers Market in Spain: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.73 Cancer Biomarkers Market in Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.74 Asia-Pacific Cancer Biomarkers Market in China: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.75 Asia-Pacific Cancer Biomarkers Market in Japan: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.76 Asia-Pacific Cancer Biomarkers Market in India: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.77 Asia-Pacific Cancer Biomarkers Market in South Korea: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.78 Asia-Pacific Cancer Biomarkers Market in Australia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.79 Asia-Pacific Cancer Biomarkers Market in New Zealand: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.80 Cancer Biomarkers Market in Latin America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.81 Latin America Cancer Biomarkers Market in Brazil: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.82 Latin America Cancer Biomarkers Market in Argentina: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.83 Latin America Cancer Biomarkers Market in Chile: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.84 Cancer Biomarkers Market in Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Table 22.85 Middle East and North Africa Cancer Biomarkers Market in Egypt: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Overall Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 7.1 Cancer Biomarker Testing Solutions: Distribution by Type of Biomarker Evaluated
Figure 7.2 Cancer Biomarker Testing Solutions: Distribution by Analytical Technique Used
Figure 7.3 Cancer Biomarker Testing Solutions: Distribution by Turnaround Time
Figure 7.4 Cancer Biomarker Testing Solutions: Distribution by Type of Sample Supported
Figure 7.5 Cancer Biomarker Testing Solutions: Distribution by Type of Nucleic Acid Tested
Figure 7.6 Cancer Biomarker Testing Solutions: Distribution by Type of Cancer
Figure 7.7 Cancer Biomarker Testing Solutions: Distribution by Application Area
Figure 7.8 Cancer Biomarker Testing Solutions: Distribution by End-user
Figure 7.9 Cancer Biomarker Testing Solution Providers: Distribution by Year of Establishment
Figure 7.10 Cancer Biomarker Testing Solution Providers: Distribution by Company Size
Figure 7.11 Cancer Biomarker Testing Solution Providers: Distribution by Location of Headquarters (Region)
Figure 7.12 Most Active Players: Distribution by Number of Testing Solutions Offered
Figure 8.1 Product Competitiveness Analysis: Overview of Peer Group I
Figure 8.2 Product Competitiveness Analysis: Overview of Peer Group II
Figure 8.3 Product Competitiveness Analysis: Overview of Peer Group III
Figure 8.4 Product Competitiveness Analysis: Cancer Biomarkers Testing Solution Offered by Providers Headquartered in North America (Peer Group I)
Figure 8.5 Product Competitiveness Analysis: Cancer Biomarkers Testing Solution Offered by Providers Headquartered in Europe (Peer Group II)
Figure 8.6 Product Competitiveness Analysis: Cancer Biomarkers Testing Solution Offered by Providers Headquartered in Asia-Pacific (Peer Group III)
Figure 10.1 Enrichment Clinical Trial Design: Steps Involved
Figure 10.2 All-Comers Clinical Trial Design: Steps Involved
Figure 10.3 Hybrid Clinical Trial Design: Steps Involved
Figure 10.4 Adaptive Clinical Trial Design: Steps Involved
Figure 11.1 Clinical Trial Analysis: Distribution by Trial Registration Year, 2022-2025
Figure 11.2 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, 2022-2025
Figure 11.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 11.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 11.8 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 11.9 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 11.10 Clinical Trial Analysis: Distribution by Type of Masking
Figure 11.11 Clinical Trial Analysis: Distribution by Type of Primary Purpose
Figure 11.12 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.13 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 11.14 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 11.15 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 11.16 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 11.17 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 12.1 Publication Analysis: Cumulative Year-wise Trend of Publications, 2019-2023
Figure 12.2 Publication Analysis: Distribution by Type of Publication
Figure 12.3 Publication Analysis: Distribution by Type of Cancer
Figure 12.4 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 12.5 Word Cloud Analysis: Emerging Focus Areas
Figure 12.6 Most Active Publishers: Distribution by Number of Publications
Figure 12.7 Key Journals: Distribution by Impact Factor
Figure 12.8 Key Journals: Distribution by Number of Publications
Figure 13.1 Spider Web Analysis: Abbott
Figure 13.2 Spider Web Analysis: AbbVie
Figure 13.3 Spider Web Analysis: Amgen
Figure 13.4 Spider Web Analysis: AstraZeneca
Figure 13.5 Spider Web Analysis: Bayer
Figure 13.6 Spider Web Analysis: Boehringer Ingelheim
Figure 13.7 Spider Web Analysis: Bristol-Myers Squib
Figure 13.8 Spider Web Analysis: Eli Lilly
Figure 13.9 Spider Web Analysis: Gilead
Figure 13.10 Spider Web Analysis: GlaxoSmithKline
Figure 13.11 Spider Web Analysis: Merck
Figure 13.12 Spider Web Analysis: Novartis
Figure 13.13 Spider Web Analysis: Pfizer
Figure 13.14 Spider Web Analysis: Roche
Figure 13.15 Spider Web Analysis: Sanofi
Figure 13.16 Benchmarking Analysis: Big Pharma players
Figure 14.1 Companion Diagnostics: Value Chain
Figure 14.2 Companion Diagnostics: Cost Distribution Across Value Chain
Figure 14.3 Costs Associated with Research and Product Development
Figure 14.4 Costs Associated with Manufacturing and Assembly
Figure 14.5 Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
Figure 14.6 Costs Associated with Payer Negotiation and KOL Engagement
Figure 14.7 Costs Associated with Marketing and Sales
Figure 15.1 Cancer Biomarkers Market: Future Growth Opportunities
Figure 16.1 Global Cancer Biomarkers Market: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 16.2 Global Cancer Biomarkers Market: Forecasted Estimates (till 2035): Conservative Scenario (USD Billion)
Figure 16.3 Global Cancer Biomarkers Market: Forecasted Estimates (till 2035): Optimistic Scenario (USD Billion)
Figure 17.1 Cancer Biomarkers Market: Distribution by Type of Biomarker
Figure 17.2 Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.3 Cancer Biomarkers Market for MET Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.4 Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.5 Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.6 Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.7 Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.8 Cancer Biomarkers Market for Other Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.9 Cancer Biomarkers Market: Distribution of Novel Biomarkers
Figure 17.10 Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.11 Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.12 Cancer Biomarkers Market for Indel Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.13 Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.14 Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 17.15 Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.1 Cancer Biomarkers Market: Distribution by Type of Cancer
Figure 18.2 Cancer Biomarkers Market for Breast Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.3 Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.4 Cancer Biomarkers Market for Lung Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.5 Cancer Biomarkers Market for Prostate Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.6 Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.7 Cancer Biomarkers Market for Bladder Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.8 Cancer Biomarkers Market for Melanoma: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.9 Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.10 Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.11 Cancer Biomarkers Market for Kidney Cancer: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 18.12 Cancer Biomarkers Market for Leukemia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.1 Cancer Biomarkers Market: Distribution by Key Geographical Regions
Figure 19.2 Cancer Biomarkers Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.3 Cancer Biomarkers Market in the US: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.4 Cancer Biomarkers Market in Canada: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.5 Cancer Biomarkers Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.6 Cancer Biomarkers Market in Germany: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.7 Cancer Biomarkers Market in France: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.8 Cancer Biomarkers Market in the UK: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.9 Cancer Biomarkers Market in Italy: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.10 Cancer Biomarkers Market in Spain: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.11 Cancer Biomarkers Market in Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.12 Cancer Biomarkers Market in China: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.13 Cancer Biomarkers Market in Japan: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.14 Cancer Biomarkers Market in India: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.15 Cancer Biomarkers Market in South Korea: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.16 Cancer Biomarkers Market in Australia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.17 Cancer Biomarkers Market in New Zealand: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.18 Cancer Biomarkers Market in Latin America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.19 Cancer Biomarkers Market in Brazil: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.20 Cancer Biomarkers Market in Argentina: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.21 Cancer Biomarkers Market in Chile: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.22 Cancer Biomarkers Market in Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.23 Cancer Biomarkers Market in Egypt: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
Figure 19.24 Market Movement Analysis: Geographical Regions
Figure 19.25 Penetration-Growth (P-G) Matrix: Geographical Regions
Figure 20.1 Concluding Remarks: Market Landscape
Figure 20.2 Concluding Remarks: Clinical Trial Analysis
Figure 20.3 Concluding Remarks: Publication Analysis
Figure 20.4 Concluding Remarks: Market Forecast and Opportunity Analysis

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

ARUP Laboratories
Asper Biogene
BioReference
Caris Life Sciences
CeGaT
Foundation Medicine
Genekor Medical
Guardant Health
IQVIA Laborateries
Labcorp
MedGenome
NeoGenomics Laboratories
Nonacus
OncoDNA
Quest Diagnostics
Oxford Gene Technology
Personal Genome Diagnostics
PhenoPath
Positive Biosciences
Tempus
Thermo Fisher Scientific
YuceBio

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4466EUR$4,799USD£3,735GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7445EUR$7,999USD£6,226GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16752EUR$17,999USD£14,009GBP